ArticleTheranostics2011
Multimodality Imaging of Integrin α(v)β(3) Expression.
Article in Theranostics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Review
- Photodynamic therapy for prostate cancer: Recent advances, challenges and opportunities.Frontiers in oncology · 2022Review
- Radionuclide-based molecular imaging allows CAR-T cellular visualization and therapeutic monitoring.Theranostics · 2021Review
- Preparation and evaluation of aAmerican journal of nuclear medicine and molecular imaging · 2018Article
- Review
- Radiolabeled, Antibody-Conjugated Manganese Oxide Nanoparticles for Tumor Vasculature Targeted Positron Emission Tomography and Magnetic Resonance Imaging.ACS applied materials & interfaces · 2017Article
- Synthesis, Chemical Characterization and Multiscale Biological Evaluation of a Dimeric-cRGD Peptide for Targeted Imaging of αScientific reports · 2017Article
- Heat-induced-radiolabeling and click chemistry: A powerful combination for generating multifunctional nanomaterials.PloS one · 2017Article
- Photoacoustic-Based Multimodal Nanoprobes: from Constructing to Biological Applications.International journal of biological sciences · 2017Review
- Article
- Conformationally Strained trans-Cyclooctene (sTCO) Enables the Rapid Construction of (18)F-PET Probes via Tetrazine Ligation.Theranostics · 2016Article
- Targeting activated hepatic stellate cells (aHSCs) for liver fibrosis imaging.EJNMMI research · 2015Article
- TYR as a multifunctional reporter gene regulated by the Tet-on system for multimodality imaging: an in vitro study.Scientific reports · 2015Article
- Synthesis and Evaluation of 64Cu-DOTA-NT-Cy5.5 as a Dual-Modality PET/Fluorescence Probe to Image Neurotensin Receptor-Positive Tumor.Molecular pharmaceutics · 2015Article
- Superparamagnetic core/shell GoldMag nanoparticles: size-, concentration- and time-dependent cellular nanotoxicity on human umbilical vein endothelial cells and the suitable conditions for magnetic resonance imaging.Journal of nanobiotechnology · 2015Article
- Tumor vasculature targeted photodynamic therapy for enhanced delivery of nanoparticles.ACS nano · 2014Article
- Fe5C2 nanoparticles with high MRI contrast enhancement for tumor imaging.Small (Weinheim an der Bergstrasse, Germany) · 2014Article
- Iodinated oil-loaded, fluorescent mesoporous silica-coated iron oxide nanoparticles for magnetic resonance imaging/computed tomography/fluorescence trimodal imaging.International journal of nanomedicine · 2014Article
- Anti-tumor effect of integrin targeted (177)Lu-3PRGD2 and combined therapy with Endostar.Theranostics · 2014Article
- The role of molecular imaging in diagnosis of deep vein thrombosis.American journal of nuclear medicine and molecular imaging · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the last decade, integrin α(v)β(3) has been studied with every single molecular imaging modality. Since no single modality is perfect and sufficient to obtain all the necessary information for a particular question, combination of certain molecular imaging modalities can offer synergistic advantages over any modality alone. This review will focus on multimodality imaging of integrin α(v)β(3) expression, where the contrast agent used can be detected by two or more imaging modalities, such as combinations of PET and optical, SPECT and fluorescence, PET and MRI, SPECT and MRI, and lastly, MRI and fluorescence. Most of these agents are based on certain type(s) of nanoparticles. Contrast agents that can be detected by more than two imaging modalities are expected to emerge in the future and a PET/MRI/fluorescence agent will likely find the most future biomedical/clinical applications. Big strides have been made over the last decade for imaging integrin α(v)β(3) expression and several PET/SPECT probes have been tested in human studies. For dualmodality and multimodality imaging applications, a number of proof-of-principle studies have been reported which opened up many new avenues for future research. The next decade will likely witness further growth and continued prosperity of molecular imaging studies focusing on integrin α(v)β(3), which can eventually impact patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.